TRX in general regulates protein-nucleic acid interactions through the redox regulation of cystein residues

[34]. In addition, cellular redox status is pivotal to regulation of apoptosis. TRX has been shown to bind and inactivate learn more apoptosis signal-regulating kinase 1 (ASK1), with the latter to be released upon oxidative stress [35]. Apart from its cellular functions, TRX can be secreted as an autocrine growth factor by a yet unknown mechanism. It is then stimulating the proliferation of cells derived from a variety of solid tumors [36]. In addition, the cytochrom P450 subtype 1B1 (CYP1B1) converts 17β-estradiol (abbreviated as E2) into the carcinogenic 4-hydroxyestradiol (4-OHE2). A study conducted in ER-positive MCF-7 breast cancer cells suggested TRX to be involved in the constitutive expression of CYP1B1 and the dioxin mediated induction of CYP1B1 [37]. It may, thus, be a potent co-factor of mammary carcinogenesis at least in estradiol responsive tumours. Like other thiol-containing proteins, thioredoxin overexpression was suspected triggering chemotherapy resistance [24]. Hence, TRX overexpression in several tumour derived

cell lines Ralimetinib mw is associated with resistance to Cisplatin [38]. However, TRX effects on anti-cancer drug resistance are complex and depend strictly on the tissue type. For instance, hepatocellular carcinoma cells with elevated thioredoxin levels are resistant to Cisplatin, but not to the antracyclin Doxorubicin [39]. However, bladder- and prostate cancer cell lines Non-specific serine/threonine protein kinase with TRX

overexpression are Cisplatin resistant and cross-resistant to Doxorubicin [40]. Cisplatin resistance in ovarian cancer cell lines is associated with high TRX levels, but recombinant TRX overexpression in non-resistant cells does not confer resistance to Cisplatin or Doxorubicin [41]. Thus, Cisplatin-responsiveness of a given tumour entity overexpressing TRX is unpredictable at present. Breast cancer For midaged women in the industrialized countries, breast cancer is the second most common cause of cancer-death [10]. Carcinomas of the mammary gland comprise rather different diseases referring to divergent cell types found in the female breast. Breast cancers are divided into ductal, medullary, lobar, papillary, tubular, apocrine and adeno-carcinomas, respectively [42]. Breast cancer is not a purely gynecological disorder: approximately 1% of breast cancer cases are male patients. Apart from histological classification, breast cancers are biochemically categorized independent of the tissue origin with respect to their receptor status: 1. HER-2 positive tumours   2. triple-negative breast cancer (TNBC), which are ER, PR, and HER-2 negative   3. endocrine-responsive tumours   HER-2 positive tumours are selleck compound characterized by constitutive overexpression of the HER-2 receptor subtype of the epidermal growth factor receptor family.